Cargando…
Prevalence of Fatigue and Unrecognized Depression in Patients with Inflammatory Bowel Disease in Remission under Immunosuppressants and Biologicals
Background: Although highly prevalent among inflammatory bowel disease (IBD) patients, fatigue remains an unmet clinical need. The aim was to describe the prevalence of fatigue in an IBD population in remission and identify factors associated with fatigue. Methods: IBD patients in clinical and bioch...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471955/ https://www.ncbi.nlm.nih.gov/pubmed/34575218 http://dx.doi.org/10.3390/jcm10184107 |
_version_ | 1784574600476098560 |
---|---|
author | Truyens, Marie De Ruyck, Elodie Gonzales, Gerard Bryan Bos, Simon Laukens, Debby De Vos, Martine |
author_facet | Truyens, Marie De Ruyck, Elodie Gonzales, Gerard Bryan Bos, Simon Laukens, Debby De Vos, Martine |
author_sort | Truyens, Marie |
collection | PubMed |
description | Background: Although highly prevalent among inflammatory bowel disease (IBD) patients, fatigue remains an unmet clinical need. The aim was to describe the prevalence of fatigue in an IBD population in remission and identify factors associated with fatigue. Methods: IBD patients in clinical and biochemical remission under treatment with immunomodulators or biologicals were included. Fatigue, physical tiredness and depression were assessed using the fatigue Visual Analogue Scale (fVAS), the Shortened Fatigue Questionnaire (SFQ) and the Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR), respectively. Relevant clinical and biochemical parameters were included in regression analyses to identify factors associated with physical fatigue. Results: In total, 157 IBD patients were included. Up to 45.9% of patients reported fatigue, physical tiredness was observed in 51% and depression in 10.8%. The majority of patients with subclinical depression were fatigued. Female sex (OR = 4.17 [1.55–6.78], p = 0.002) was independently associated with physical fatigue. Transferrin saturation (OR = −0.11 [−0.22–−0.007], p = 0.037) and treatment with adalimumab (compared to infliximab, OR = −3.65 [−7.21–−0.08], p = 0.045) entailed a lower risk of fatigue. Conclusion: Fatigue is observed in about half of IBD patients in remission and can be a symptom of underlying undetected depression. Sex, transferrin saturation and medication were identified as independent risk factors. |
format | Online Article Text |
id | pubmed-8471955 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84719552021-09-28 Prevalence of Fatigue and Unrecognized Depression in Patients with Inflammatory Bowel Disease in Remission under Immunosuppressants and Biologicals Truyens, Marie De Ruyck, Elodie Gonzales, Gerard Bryan Bos, Simon Laukens, Debby De Vos, Martine J Clin Med Article Background: Although highly prevalent among inflammatory bowel disease (IBD) patients, fatigue remains an unmet clinical need. The aim was to describe the prevalence of fatigue in an IBD population in remission and identify factors associated with fatigue. Methods: IBD patients in clinical and biochemical remission under treatment with immunomodulators or biologicals were included. Fatigue, physical tiredness and depression were assessed using the fatigue Visual Analogue Scale (fVAS), the Shortened Fatigue Questionnaire (SFQ) and the Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR), respectively. Relevant clinical and biochemical parameters were included in regression analyses to identify factors associated with physical fatigue. Results: In total, 157 IBD patients were included. Up to 45.9% of patients reported fatigue, physical tiredness was observed in 51% and depression in 10.8%. The majority of patients with subclinical depression were fatigued. Female sex (OR = 4.17 [1.55–6.78], p = 0.002) was independently associated with physical fatigue. Transferrin saturation (OR = −0.11 [−0.22–−0.007], p = 0.037) and treatment with adalimumab (compared to infliximab, OR = −3.65 [−7.21–−0.08], p = 0.045) entailed a lower risk of fatigue. Conclusion: Fatigue is observed in about half of IBD patients in remission and can be a symptom of underlying undetected depression. Sex, transferrin saturation and medication were identified as independent risk factors. MDPI 2021-09-11 /pmc/articles/PMC8471955/ /pubmed/34575218 http://dx.doi.org/10.3390/jcm10184107 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Truyens, Marie De Ruyck, Elodie Gonzales, Gerard Bryan Bos, Simon Laukens, Debby De Vos, Martine Prevalence of Fatigue and Unrecognized Depression in Patients with Inflammatory Bowel Disease in Remission under Immunosuppressants and Biologicals |
title | Prevalence of Fatigue and Unrecognized Depression in Patients with Inflammatory Bowel Disease in Remission under Immunosuppressants and Biologicals |
title_full | Prevalence of Fatigue and Unrecognized Depression in Patients with Inflammatory Bowel Disease in Remission under Immunosuppressants and Biologicals |
title_fullStr | Prevalence of Fatigue and Unrecognized Depression in Patients with Inflammatory Bowel Disease in Remission under Immunosuppressants and Biologicals |
title_full_unstemmed | Prevalence of Fatigue and Unrecognized Depression in Patients with Inflammatory Bowel Disease in Remission under Immunosuppressants and Biologicals |
title_short | Prevalence of Fatigue and Unrecognized Depression in Patients with Inflammatory Bowel Disease in Remission under Immunosuppressants and Biologicals |
title_sort | prevalence of fatigue and unrecognized depression in patients with inflammatory bowel disease in remission under immunosuppressants and biologicals |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471955/ https://www.ncbi.nlm.nih.gov/pubmed/34575218 http://dx.doi.org/10.3390/jcm10184107 |
work_keys_str_mv | AT truyensmarie prevalenceoffatigueandunrecognizeddepressioninpatientswithinflammatoryboweldiseaseinremissionunderimmunosuppressantsandbiologicals AT deruyckelodie prevalenceoffatigueandunrecognizeddepressioninpatientswithinflammatoryboweldiseaseinremissionunderimmunosuppressantsandbiologicals AT gonzalesgerardbryan prevalenceoffatigueandunrecognizeddepressioninpatientswithinflammatoryboweldiseaseinremissionunderimmunosuppressantsandbiologicals AT bossimon prevalenceoffatigueandunrecognizeddepressioninpatientswithinflammatoryboweldiseaseinremissionunderimmunosuppressantsandbiologicals AT laukensdebby prevalenceoffatigueandunrecognizeddepressioninpatientswithinflammatoryboweldiseaseinremissionunderimmunosuppressantsandbiologicals AT devosmartine prevalenceoffatigueandunrecognizeddepressioninpatientswithinflammatoryboweldiseaseinremissionunderimmunosuppressantsandbiologicals |